vs
Side-by-side financial comparison of UNIVEST FINANCIAL Corp (UVSP) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $87.5M, roughly 1.1× UNIVEST FINANCIAL Corp). UNIVEST FINANCIAL Corp runs the higher net margin — 31.0% vs 25.0%, a 6.0% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 10.2%).
Univest Financial Corp is a U.S. regional financial services holding company based in Pennsylvania. It offers banking, wealth management, insurance, and lending solutions for individual consumers, SMEs, and institutional clients across its Mid-Atlantic operating regions.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
UVSP vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $87.5M | $92.9M |
| Net Profit | $27.1M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 31.0% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $0.96 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $87.5M | — | ||
| Q4 25 | $84.6M | $92.9M | ||
| Q3 25 | $83.2M | $67.5M | ||
| Q2 25 | $81.0M | $63.2M | ||
| Q1 25 | $79.2M | $52.6M | ||
| Q4 24 | $76.8M | $75.4M | ||
| Q3 24 | $73.4M | $57.9M | ||
| Q2 24 | $72.0M | $52.7M |
| Q1 26 | $27.1M | — | ||
| Q4 25 | $22.7M | $23.2M | ||
| Q3 25 | $25.6M | $5.1M | ||
| Q2 25 | $20.0M | $-553.0K | ||
| Q1 25 | $22.4M | $-11.2M | ||
| Q4 24 | $18.9M | $19.8M | ||
| Q3 24 | $18.6M | $-901.0K | ||
| Q2 24 | $18.1M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 34.0% | 24.1% | ||
| Q3 25 | 38.5% | 5.1% | ||
| Q2 25 | 30.9% | -3.2% | ||
| Q1 25 | 34.8% | -24.3% | ||
| Q4 24 | 30.9% | 24.5% | ||
| Q3 24 | 31.9% | -4.3% | ||
| Q2 24 | 31.4% | -11.5% |
| Q1 26 | 31.0% | — | ||
| Q4 25 | 26.9% | 25.0% | ||
| Q3 25 | 30.8% | 7.5% | ||
| Q2 25 | 24.7% | -0.9% | ||
| Q1 25 | 28.3% | -21.4% | ||
| Q4 24 | 24.7% | 26.3% | ||
| Q3 24 | 25.3% | -1.6% | ||
| Q2 24 | 25.1% | -8.9% |
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.78 | $0.46 | ||
| Q3 25 | $0.89 | $0.10 | ||
| Q2 25 | $0.69 | $-0.01 | ||
| Q1 25 | $0.77 | $-0.23 | ||
| Q4 24 | $0.64 | $0.40 | ||
| Q3 24 | $0.63 | $-0.02 | ||
| Q2 24 | $0.62 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $222.4M | $137.5M |
| Total DebtLower is stronger | $201.2M | — |
| Stockholders' EquityBook value | $952.0M | $354.6M |
| Total Assets | $8.1B | $488.0M |
| Debt / EquityLower = less leverage | 0.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $222.4M | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
| Q1 26 | $201.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $952.0M | — | ||
| Q4 25 | $943.3M | $354.6M | ||
| Q3 25 | $933.2M | $321.9M | ||
| Q2 25 | $916.7M | $306.8M | ||
| Q1 25 | $903.5M | $295.5M | ||
| Q4 24 | $887.3M | $292.0M | ||
| Q3 24 | $877.1M | $257.5M | ||
| Q2 24 | $854.1M | $243.0M |
| Q1 26 | $8.1B | — | ||
| Q4 25 | $8.4B | $488.0M | ||
| Q3 25 | $8.6B | $453.3M | ||
| Q2 25 | $7.9B | $435.6M | ||
| Q1 25 | $8.0B | $424.6M | ||
| Q4 24 | $8.1B | $432.7M | ||
| Q3 24 | $8.2B | $390.4M | ||
| Q2 24 | $7.9B | $376.8M |
| Q1 26 | 0.21× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $101.5M | $15.0M | ||
| Q3 25 | $32.0M | $22.1M | ||
| Q2 25 | $23.3M | $8.2M | ||
| Q1 25 | $15.6M | $6.6M | ||
| Q4 24 | $75.1M | $22.2M | ||
| Q3 24 | $38.9M | $10.2M | ||
| Q2 24 | $-3.4M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $96.9M | $12.8M | ||
| Q3 25 | $31.4M | $19.5M | ||
| Q2 25 | $21.9M | $81.0K | ||
| Q1 25 | $13.7M | $-7.6M | ||
| Q4 24 | $72.0M | $8.5M | ||
| Q3 24 | $38.3M | $-9.2M | ||
| Q2 24 | $-4.2M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 114.6% | 13.8% | ||
| Q3 25 | 37.7% | 28.8% | ||
| Q2 25 | 27.0% | 0.1% | ||
| Q1 25 | 17.2% | -14.5% | ||
| Q4 24 | 93.8% | 11.2% | ||
| Q3 24 | 52.2% | -15.9% | ||
| Q2 24 | -5.9% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 2.4% | ||
| Q3 25 | 0.7% | 3.9% | ||
| Q2 25 | 1.7% | 12.9% | ||
| Q1 25 | 2.5% | 27.0% | ||
| Q4 24 | 4.0% | 18.3% | ||
| Q3 24 | 0.8% | 33.5% | ||
| Q2 24 | 1.1% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.46× | 0.65× | ||
| Q3 25 | 1.25× | 4.35× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 3.97× | 1.12× | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | -0.19× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
UVSP
| Net Interest Income | $63.4M | 72% |
| Noninterest Income | $24.1M | 28% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
